UTime Signs NDA to Acquire Monkeypox Vaccine Maker Bowen Therapeutics Inc and Supports Completion of FDA Registration of Related Vaccines

UTime Signs NDA to Acquire Monkeypox Vaccine Maker Bowen Therapeutics Inc and Supports Completion of FDA Registration of Related Vaccines (Di mercoledì 28 agosto 2024) - SHENZHEN, China, Aug. 28, 2024 /PRNewswire/

UTime Limited (NASDAQ: WTO) ("UTime" or the "Company") has officially announced the signing of a non-disclosure agreement (the "NDA") with Bowen Therapeutics Inc ("Bowen Therapeutics") for the acquisition of the Bowen Therapeutics laboratory at UMASS Medical School. This strategic move not only marks UTime's in-depth expansion in the global Vaccine market, but also provides strong support for the Registration of the relevant Vaccine through the U.S. Food and Drug Administration (the "FDA"). One of the key drivers behind this acquisition is a growing global need for an effective Monkeypox Vaccine. Monkeypox, as an infectious disease caused by the Monkeypox virus, has broken out in many places around the world in recent years, causing a high degree of alertness in the international community.Leggi tutta la notizia su liberoquotidiano